OverviewSuggest Edit

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. The Company's purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
TypePublic
Founded2002
HQSouth Brunswick Township, US
Websitecytosorbents.com

Latest Updates

Employees (est.) (Sep 2017)65
Revenue (FY, 2017)$15.2 M(+60%)
Share Price (Jun 2019)$6.4

Key People/Management at Cytosorbents

Phillip Chan

Phillip Chan

Chief Executive Officer and President
Kathleen Bloch

Kathleen Bloch

CFO
Vincent Capponi

Vincent Capponi

COO
Robert Bartlett

Robert Bartlett

Chief Medical Officer
Show more

Cytosorbents Office Locations

Cytosorbents has an office in South Brunswick Township
South Brunswick Township, US (HQ)
7 Deerpark Dr, Monmouth Junction
Show all (1)

Cytosorbents Financials and Metrics

Cytosorbents Revenue

Embed Graph
View revenue for all periods
Cytosorbents's revenue was reported to be $15.15 m in FY, 2017 which is a 59% increase from the previous period.
USD

Revenue (FY, 2017)

15.2m

Revenue growth (FY, 2016 - FY, 2017), %

59%

Gross profit (FY, 2017)

9.6m

Gross profit margin (FY, 2017), %

63.6%

Net income (FY, 2017)

(8.5m)

EBIT (FY, 2017)

(9.8m)

Market capitalization (10-Jun-2019)

207.7m

Closing stock price (10-Jun-2019)

6.4

Cash (31-Dec-2017)

17.3m

EV

200.4m
Cytosorbents's current market capitalization is $207.7 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

4.8m9.5m15.2m

Revenue growth, %

99%59%

Cost of goods sold

2.2m4.0m5.5m

Gross profit

2.6m5.6m9.6m
USDFY, 2015FY, 2016FY, 2017

Cash

5.3m5.2m17.3m

Accounts Receivable

648.9k1.4m2.2m

Prepaid Expenses

511.9k315.8k416.0k

Inventories

1.2m834.0k795.7k
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1m)(11.8m)(8.5m)

Depreciation and Amortization

113.0k161.6k218.3k

Inventories

(671.3k)340.4k57.3k

Accounts Payable

(83.2k)2.1m523.4k
USDY, 2017

EV/EBIT

-17.2 x

EV/CFO

-26.2 x

Revenue/Employee

233.1k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.3 x

P/E Ratio

(17.1)
Show all financial metrics

Cytosorbents Online and Social Media Presence

Embed Graph

Cytosorbents News and Updates

CytoSorbents Highlights Recent Published Studies on CytoSorb

MONMOUTH JUNCTION, N.J., Aug. 28, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights...

CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan

MONMOUTH JUNCTION, N.J., Aug. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces it...

CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London

MONMOUTH JUNCTION, N.J., April 8, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced...

Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor

MONMOUTH JUNCTION, N.J., March 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...

CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018

MONMOUTH JUNCTION, N.J., March 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...

CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands

MONMOUTH JUNCTION, N.J., March 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...
Show more

Cytosorbents Blogs

CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference

MONMOUTH JUNCTION, N.J., Sept. 9, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that…

CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022

MONMOUTH JUNCTION, N.J., Aug. 15, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb …

CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica

MONMOUTH JUNCTION, N.J., Aug. 13, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, expands CytoSorb distrib…

CytoSorbents Reports Record Second Quarter 2019 Financial Results

Q2 2019 Total Revenue was $6.2 million, with record quarterly product sales of $5.9 million and product gross margins of 76% MONMOUTH JUNCTION, N.J., Aug. 6, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification techn…

CytoSorbents to Report Q2 2019 Operating and Financial Results

MONMOUTH JUNCTION, N.J., July 30, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 …

CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference

MONMOUTH JUNCTION, N.J., June 11, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that…
Show more

Cytosorbents Frequently Asked Questions

  • When was Cytosorbents founded?

    Cytosorbents was founded in 2002.

  • Who are Cytosorbents key executives?

    Cytosorbents's key executives are Phillip Chan, Kathleen Bloch and Vincent Capponi.

  • How many employees does Cytosorbents have?

    Cytosorbents has 65 employees.

  • What is Cytosorbents revenue?

    Latest Cytosorbents annual revenue is $15.2 m.

  • What is Cytosorbents revenue per employee?

    Latest Cytosorbents revenue per employee is $233.1 k.

  • Who are Cytosorbents competitors?

    Competitors of Cytosorbents include Smith & Nephew, Apollo Endosurgery and Xenex Disinfection Services.

  • Where is Cytosorbents headquarters?

    Cytosorbents headquarters is located at 7 Deerpark Dr, Monmouth Junction, South Brunswick Township.

  • Where are Cytosorbents offices?

    Cytosorbents has an office in South Brunswick Township.

  • How many offices does Cytosorbents have?

    Cytosorbents has 1 office.